Literature DB >> 28917669

Knowledge-driven computational modeling in Alzheimer's disease research: Current state and future trends.

Hugo Geerts1, Martin Hofmann-Apitius2, Thomas J Anastasio3.   

Abstract

Neurodegenerative diseases such as Alzheimer's disease (AD) follow a slowly progressing dysfunctional trajectory, with a large presymptomatic component and many comorbidities. Using preclinical models and large-scale omics studies ranging from genetics to imaging, a large number of processes that might be involved in AD pathology at different stages and levels have been identified. The sheer number of putative hypotheses makes it almost impossible to estimate their contribution to the clinical outcome and to develop a comprehensive view on the pathological processes driving the clinical phenotype. Traditionally, bioinformatics approaches have provided correlations and associations between processes and phenotypes. Focusing on causality, a new breed of advanced and more quantitative modeling approaches that use formalized domain expertise offer new opportunities to integrate these different modalities and outline possible paths toward new therapeutic interventions. This article reviews three different computational approaches and their possible complementarities. Process algebras, implemented using declarative programming languages such as Maude, facilitate simulation and analysis of complicated biological processes on a comprehensive but coarse-grained level. A model-driven Integration of Data and Knowledge, based on the OpenBEL platform and using reverse causative reasoning and network jump analysis, can generate mechanistic knowledge and a new, mechanism-based taxonomy of disease. Finally, Quantitative Systems Pharmacology is based on formalized implementation of domain expertise in a more fine-grained, mechanism-driven, quantitative, and predictive humanized computer model. We propose a strategy to combine the strengths of these individual approaches for developing powerful modeling methodologies that can provide actionable knowledge for rational development of preventive and therapeutic interventions. Development of these computational approaches is likely to be required for further progress in understanding and treating AD.
Copyright © 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  OpenBEL; Predictive platform; Process-oriented modeling; Quantitative systems pharmacology; Target validation

Mesh:

Year:  2017        PMID: 28917669     DOI: 10.1016/j.jalz.2017.08.011

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  3 in total

1.  Binding site matching in rational drug design: algorithms and applications.

Authors:  Misagh Naderi; Jeffrey Mitchell Lemoine; Rajiv Gandhi Govindaraj; Omar Zade Kana; Wei Pan Feinstein; Michal Brylinski
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

Review 2.  Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease.

Authors:  Alok Joshi; Da-Hui Wang; Steven Watterson; Paula L McClean; Chandan K Behera; Trevor Sharp; KongFatt Wong-Lin
Journal:  Neuropharmacology       Date:  2020-05-04       Impact factor: 5.250

3.  Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.

Authors:  Hugo Geerts; John Wikswo; Piet H van der Graaf; Jane P F Bai; Chris Gaiteri; David Bennett; Susanne E Swalley; Edgar Schuck; Rima Kaddurah-Daouk; Katya Tsaioun; Mary Pelleymounter
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-11-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.